12:00 AM
Aug 19, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Supinoxin: Phase I started

Rexahn began a dose-escalation Phase I trial to evaluate oral RX-5902 in patients with solid tumors.

Rexahn Pharmaceuticals Inc. (NYSE-M:RNN),...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >